EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER
Liver Cancer Summit 202422-24 February, Rotterdam
N. Poster
Poster title
Applicant name
Status
 |
|
|
|
| 1-PO2 | A modified Charlson Comorbidity Index to improve management of patients with hepatocellular carcinoma: a step towards precision medicine | Eleonora Alimenti |  Received |
 |
|||
| 1-PO8 | Efficacy and safety of atezolizumab-bevacizumab for hepatocellular carcinoma in real-life clinical practice: data from a multicenter collaborative study | Bernardo Stefanini | Received |
|
|||
| 1-PO3 | Role of Nrf2 signaling in the crosstalk between Trx1 and GSNOR-redox regulators in liver cancer cells | Natalia García-Villasante | Received |
|
|||
| 1-PO6 | Characterization of ENTOSIS, a cell cannibalism process, in HEPATOCELLULAR CARCINOMA | Violaine Moreau | Received |
|
|||
| 1-PO5 | Idarubicin-infused transarterial chemoembolization (TACTida) as potential therapy for HCC-patients : Clinical and ex-vivo assessment of drug response and survival to varying IDA concentrations | Jaafar Khaled | Received |
|
|||
| 1-PO4 | Targeting endoplasmic reticulum-stress pathways : AMG-PERK and TUDCA inhibitors as potential repressors for hepatocellular carcinoma progression | Jaafar Khaled | Received |
|
|||
| 1-PO7 | a-FAtE: a new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma incorporating a-Fetoprotein, Alkaline phosphatase and Eosinophil count | Federico Rossari | Received |
|
|||
| 2-PO4 | Cholangiocarcinoma across England: evidence of regional, socioeconomic, and temporal variation in incidence, survival, routes to diagnosis and treatment | Shahid Khan | Received |
|
|||
| 2-PO7 | Erodosteine attenuates metabolic dysfunction-associated fatty liver disease in experimental animals: molecular pathway insight | Jatin Sharma | Received |
|
|||
| 2-PO3 | Volumetry-based assessment of post-hepatectomy liver failure | Alexander Gerlach | Received |
|
|||
| 2-PO6 | Involvment of the potassium channel ERG1 in cholangiocarcinoma | Mirella Pastore | Received |
|
|||
| 2-PO1 | Circulating hypermethylated RASSF1A as a marker of hepatocellular carcinoma in chronic HCV patients | Mohamed Abdel-Samiee | Received |
|
|||
| 2-PO2 | effect of atorvastatin together with rifaximin in the prevention of hepatocarcinogenesis generated by dioxin-type toxic | Mario Álvares-Da-Silva | Received |
|
|||
| 2-PO8 | Readability, reliability, and accuracy of publicly available large language models on liver cancer diagnosis and management | Justin Tse | Received |
|
|||
| 2-PO5 | Emerging role of oncogenic -CATENIN in EXOSOME biogenesis as a driver of IMMUNE ESCAPE in hepatocellular carcinoma | Violaine Moreau | Received |
|
|||
| 3-PO2 | Treatment of Hepatocellular Carcinoma according to multiparametric therapeutic hierarchy approach: a prospective multicenter validation study | Lorenzo Canova | Received |
|
|||
| 3-PO8 | High viscoelasticity promotes the progression of hepatocellular carcinoma (HCC) in pre-cirrhotic livers | Lorand Vancza | Received |
|
|||
| 3-PO5 | Targeting hepatocellular carcinoma: evaluation of vicinal diaryl isoxazole and pyrazole derivatives with implications for oxidative stress and senescence-mediated anti-tumor mechanisms | Esra Nalbat | Received |
|
|||
| 3-PO1 | Evaluation of glycemia and diabetes as prognostic factors in advanced hepatocellular carcinoma treated with systemic therapy | Antonio Acquaviva | Received |
|
|||
| 3-PO6 | Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients progressed to atezolizumab plus bevacizumab (AB) | Mara Persan | Received |
|
|||
| 3-PO7 | Better endpoints of outcome comparisons between HAIC and Sorafenib in advanced hepatocellular carcinoma: a systematic review and meta-analysis | TENGFEI SI | Received |
|
|||
| 3-PO3 | MAP17 stimulates mitochondrial activity by enhancing one-carbon metabolism, leading to the promotion of EMT in hepatocellular carcinomas (HCCs) | CLÀUDIA GIL PITARCH | Received |
|
|||
| 3-PO4 | Development of microenvironment-dependent hepatocellular carcinoma and colorectal liver metastasis spheroid culture models | Elisabeth Knetemann | Received |
|
|||
| 4-PO3 | Analytical and clinical evaluation of a novel enzyme-immunoassay for the measurement of circulating protein induced by vitamin K absence or antagonist II in patients with hepatocellular carcinoma of viral-etiology | Marta Guariglia | Received |
|
|||
| 4-PO2 | HCC incidence and risk stratification in patients with metabolic dysfunction-associated steatotic liver disease on long-term follow-up | Gian Paolo Caviglia | Received |
|
|||
| 4-PO6 | Evolution of liver function during immune checkpoint inhibitor treatment for hepatocellular carcinoma | Katharina Pomej | Received |
|
|||
| 4-PO5 | Revolutionizing post-surgical outcome predictions: non-invasive tests and AI for hepatocellular carcinoma patients | Iuliana Nenu | Received |
|
|||
| 4-PO8 | Establishment of a national Hepatocellular carcinoma service has addressed regional inequality in access to treatments including liver transplant | Ambily Tony | Received |
|
|||
| 4-PO4 | Inhibiting the endoplasmic reticulum stress response enhances the effect of doxorubicin by altering the lipid metabolism of liver cancer cells | MARIA KOPSIDA | Received |
|
|||
| 4-PO7 | The detrimental effect of metabolic risk factors on GENDER DIFFERENCES in HCC development and treatment allocation. | Daniel Smith | Received |
|
|||
| 4-PO1 | Improved handling of BCLC 2022 update in the management of hepatocellular carcinoma in clinical practice | Eleonora Alimenti | Received |
|
|||
| 5-PO6 | The impact of AGE and GENDER on the SURVIVAL of patients diagnosed with HEPATOCELLULAR carcinoma | Pompilia Radu | Received |
|
|||
| 5-PO1 | Extracellular vesicles size, concentration and different miRNA expression when compared with serum in MASLD: from steatosis to hepatocellular carcinoma | Mario Álvares-Da-Silva | Received |
|
|||
| 5-PO8 | Demographic and clinical features of the patients diagnosed with hepatocellular carcinoma in Spain: Results of the III Registry of the Spanish Association for the Study of the Liver (AEEH) | Maria Varela | Received |
|
|||
| 5-PO4 | Impact of glucose homeostasis on postoperative complications after major hepatectomies | Paul Krebs | Received |
|
|||
| 5-PO7 | Prognostic value of ultra-low-pass whole genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment | Miguel Sogbe | Received |
|
|||
| 5-PO2 | Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma compared to patients with advanced solid tumours | Ciro Celsa | Received |
|
|||
| 5-PO3 | 1-Piperidine propionic acid is effective in reducing HCC development and fatty acid accumulation in experimental liver carcinogenesis | Pietro Guerra | Received |
|
|||
| 6-PO3 | Transcriptomic landscape of epigenetic effectors in human cholangiocarcinoma | Maite G Fernandez-Barrena | Received |
|
|||
| 6-PO1 | Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab | Elisabeth Amade | Received |
|
|||
| 6-PO8 | Household income is associated with a higher likelihood of receiving curative treatment in hepatocellular carcinoma | Juan Vaz | Received |
|
|||
| 6-PO5 | Being part of surveillance programme alone improves early-stage hepatocellular carcinoma detection | Adina Olaru | Received |
|
|||
| 6-PO2 | Exploring the role of aMAP and Toronto score: beyond diagnosis to prognosis | Annalisa Cespiati | Received |
|
|||
| 6-PO7 | Pre-treatment serum N-glycans predict poor immunotherapy response and survival in Hepatocellular Carcinoma | Nicky Somers | Received |
|
|||
| 6-PO6 | Assessment of liver fibrosis with transient elastography in non-alcoholic fatty liver disease patients; a real-life experience from pakistan | Lajpat Rai | Received |
|
|||
| 6-PO4 | Sorafenib as a second-line treatment after failure of atezolizumab-bevacizumab | Lorenzo Lani | Received |
|
|||
| 7-PO3 | Role of nitric oxide in cell resistance to Sorafenib in HepG2 cell line | Thaissa Horne | Received |
|
|||
| 7-PO2 | Extrachromosomal circular DNA facilitates the crosstalk between hepatocytes and immune cells through the cGAS-STING pathway to promote immune response and HCC | Lap Kwan Chan | Received |
|
|||
| 7-PO4 | Bile extracellular vesicles hold protein biomarkers for the early diagnosis of cholangiocarcinoma in individuals with primary sclerosing cholangitis | Ainhoa Lapitz | Received |
|
|||
| 7-PO7 | Prophylaxis of variceal bleeding in patients receiving atezolizumab-bevacizumab for hepatocellular carcinoma | Benedetta Stefanini | Received |
|
|||
| 7-PO6 | Competitive Risk Analysis of Spleen Stiffness Measurement with a Spleen-Dedicated Module (SSM@100Hz) for Predicting de-novo HCC Occurrence in cACLD Patients: A prospective 5-Year Follow-up Study | Federico Ravaioli | Received |
|
|||
| 7-PO1 | Integrated hepatitis testing and treatment intervention among people who inject drugs: a comprehensive approach to increase linkage to care towards prevention of progression to hepatocellular carcinoma | Rijimra Ande | Received |
|
|||
| 7-PO5 | Differential Expression of MicroRNA-21 in MASLD and HCV-Related Hepatocellular Carcinoma: A Pilot Study | Claudia Oliveira | Received |
|
|||
| 8-PO7 | Do ACE inhibitors have a role in preventing drug-related proteinuria in advanced HCC patients? | Bernardo Stefanini | Received |
|
|||
| 8-PO1 | Pirfenidone promotes tumor cell elimination via increased infiltration of cytotoxic cells and by limiting fibrosis and responses of regulatory T cells in an experimental hepatocellular carcinoma model | Scarlet Arceo-Orozco | Received |
|
|||
| 8-PO2 | Aetiology of hepatocellular carcinoma and response to immunotherapy: is the the problem inherent in the classification of non-viral disease? | Rusi Chen | Received |
|
|||
| 8-PO6 | Cancer associated fibroblast plasticity and interaction with the tumour microenvironment in cholangiocarcinoma | Aashreya Ravichandra | Received |
|
|||
| 8-PO5 | Improvement of quality of care and patient satisfaction for patients with hepatocellular carcinoma via implementation of a specialist nurse a pilot study | Larissa Pajancic | Received |
|
|||
| 8-PO3 | cholangiocarcinoma patient-derived organoids: an in vitro platform for antibody-drug conjugates sensitivity testing | Racha Hosni | Received |
|
|||
| 8-PO4 | TM4SF5-NCOA3-PTEN linkage for albumin uptake and bioenergetics during HCC progression | Jung Weon Lee | Received |
|
|||
| 9-PO6 | Unveiling TIGAR SUMOylation in the metabolic response of liver cancer. | Claudia M. Rejano Gordillo | Received |
|
|||
| 9-PO4 | MiR-22 downregulation activates HIF-1A pathway and induces tumor progression, metabolic reprogramming and sorafenib resistance in hepatocellular carcinoma | Ilaria Leoni | Received |
|
|||
| 9-PO7 | Does AtezoBev present as a safe and efficacious treatment option for hepatocellular carcinoma in patients with Child-Pugh B cirrhosis? A retrospective multicentric real-world study. | Leonardo Stella | Received |
|
|||
| 9-PO2 | Investigating the immunogenetic heterogeneity in hepatocellular carcinoma | Abigail Connor | Received |
|
|||
| 9-PO5 | Novel ctDNA technology for liver cancer detection by immunoprecipitation of tumor associated ctDNA fragments and analysis by qPCR | Dorian Pamart | Received |
|
|||
| 9-PO1 | Usefulness of inhibiting the drug-export pump MRP3 for sensitizing cholangiocarcinoma to chemotherapy | Maitane Asensio | Received |
|
|||
| 9-PO8 | Impact of hospital stay on complications and long-term outcomes after major hepatectomies | Nick Winkler | Received |
|
|||
| 9-PO3 | Comparative analysis of subclassification models in patients with intermediate stage hepatocellular carcinoma (BCLC B) receiving systemic therapy | Ielasi Luca | Received |
|
|||
| 10-PO3 | Locoregional control of proton beam therapy for hepatocellular carcinoma with extrahepatic lymph node metastasis | Takashi Iizumi | Received |
|
|||
| 10-PO1 | Developing a data-driven framework to assess the performance and value of multi-disciplinary teams in HCC | Pablo Azcue | Received |
|
|||
| 10-PO5 | Non-viral etiology with low baseline neutrophil to lymphocyte ratio (NLR) and liver disease severity could predict clinical outcome in Atezolizumab-Bevacizumab treated Caucasian cirrhotic patients with advanced HCC | Spyridon Pantzios | Received |
|
|||
| 10-PO8 | Thrombocytopenia did not increase Radiofrequency Ablation- related bleeding risk in patients with hepatocellular carcinoma and cirrhosis | Songchi Xiao | Received |
|
|||
| 10-PO6 | Circular RNAs in hepatocellular carcinoma: the study of hsa_circ_0062682 | Tadeja Rezen | Received |
|
|||
| 10-PO2 | Impact of Body Mass Index on the prognosis of unresectable HCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab | NOEMI CORNARA | Received |
|
|||
| 10-PO4 | Histological and molecular characterization of GAN diet-induced obese mouse model of advanced fibrosing MASH with progression to HCC | Monika Lewinska | Received |
|
|||
| 11-PO1 | Differential deregulation of the metabolome during liver cancer progression and regression. | Asha Balakrishnan | Received |
|
|||
| 11-PO8 | A Novel Muti-tactic Approach to Block Immune Checkpoints PD-1/PD-L1 and CD155/TIGIT in Hepatocellular Carcinoma using an array of Non-coding RNAs | Rana Youness | Received |
|
|||
| 11-PO2 | The presence of hepatocellular carcinoma (HCC) does not influence the rebalanced hemostasis in patients with cirrhosis | Rares Craciun | Received |
|
|||
| 11-PO5 | Imparing proliferation, survival and invasiveness of Intrahepatic Cholangiocarcinoma through a novel natural Hedgehog pathway inhibitor. | Savino Paradiso | Received |
|
|||
| 11-PO4 | Sensitization of cholangiocarcinoma to chemotherapy by -caryophyllene oxide-induced BCRP inhibition | Rocio Macias | Received |
|
|||
| 11-PO6 | Caspases compromise SLU7 and UPF1 stability and nonsense-mediated RNA decay activity during hepatocarcinogenesis | Carla Rojo | Received |
|
|||
| 11-PO3 | Risk of malignancy in patients with liver transplantation | Zülal &304;stemihan | Received |
|
|||
| 12-PO7 | Declining Hepatitis C virus-related Hepatocellular Carcinoma Mortality in the Direct-Acting Antiviral Therapy Era in the United States, From 1999 to 2021 | Muhammad Ali Tariq | Received |
|
|||
| 12-PO2 | The synergic effect of metformin with atezolizumab/bevacizumab in MASLD HCC patients: a retrospective study from ARTE multicentric Italian dataset | Dalbeni Andrea | Received |
|
|||
| 12-PO1 | High-dimensional spatial profiling of the hepatocellular carcinoma tumor microenvironment reveals spatial immune types informing immune checkpoint inhibitor therapy response | Bertram Bengsch | Received |
|
|||
| 12-PO8 | Atezolizumab-targeted liposomal doxorubicin modulates PD-L1 expression and reduces the invasive phenotype in in vitro models of hepatocellular carcinoma | Ilaria Zanotto | Received |
|
|||
| 12-PO4 | In silico electrophysiology investigation unveils cardiotoxicity Induced by Tecentric, a crucial therapeutic agent for hepatocellular carcinoma, through sodium current inhibition. | Chitaranjan Mahapatra | Received |
|
|||
| 12-PO5 | Role of ganglioside GD2 in the stem-like compartment of intrahepatic cholangiocarcinoma | Mirella Pastore | Received |
|
|||
| 12-PO3 | Circulating vesicle microRNAs for metabolic dysfunction-associated steatotic liver disease (MASLD) staging and progression towards liver cancer | Santiago Iturbe-Rey | Received |
|
|||
| 12-PO6 | Dissociation between acute liver decompensation and radiological response in patients with hepatocellular carcinoma treated with atezolizumab-bevacizumab | Martina Rosi | Received |
|
|||
| 13-PO4 | The correlation between Interleukin-6 and the progression of chronic Hepatitis B | MOHAMED SHAFI MAHBOOB ALI | Received |
|
|||
| 13-PO3 | Combined extracellular matrix remodelling by cyclophilin inhibitor rencofilstat and immune checkpoint blockade as a potential therapy for intrahepatic cholangiocarcinoma. | Ravi Jagatia | Received |
|
|||
| 13-PO2 | Modeling cancer cells and tumor vasculature dynamics by serum biomarkers in HCC patients with different response to TKIs, TACE and TARE suggests a synergistic effect of systemic and endovascular treatments | Francesco Damone | Received |
|
|||
| 13-PO5 | Aptamers targeting HuR SUMOylation as a potential therapy for liver cancer | Patricia Peña-San Felix | Received |
|
|||
| 13-PO6 | The prognostic impact of viral and non-viral etiologies on advanced hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a real-world, multicenter study | Federico Rossari | Received |
|
|||
| 13-PO1 | Inhibition of the transmembrane transporter ABCB1 overcomes resistance to doxorubicin in patient-derived organoid models of hepatocellular carcinoma | Lauriane Blukacz | Received |
|
|||
| 13-PO7 | The role of tumor molecular profiling in patients with advanced biliary tract cancer receiving systemic treatment | Giulia Tesini | Received |
|
|||
| 13-PO8 | Biliary tract cancers (BTC): molecular profiling and matched therapy | Valentina Zanuso | Received |
|
|||
| 14-PO1 | The impact of the onset of hepatocellular carcinoma on the natural history of cirrhosis | Silvia Cagnin | Received |
|
|||
| 14-PO3 | The awareness of the link between liver cancer and hepatitis as a motivation for action results of a globally representative survey | Alexandra Smith | Received |
|
|||
| 14-PO4 | Identification of factors associated with primary refractoriness to atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma | Giulia Francesca Manfredi | Received |
|
|||
| 14-PO6 | Proteomic profiling of HCC reveals the involvement of energy metabolism in treatment response | Frederic Saltel | Received |
|
|||
| 14-PO5 | Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB) | Mara Persano | Received |
|
|||
| 14-PO8 | Implications and therapeutic potential of neddylation for pediatric liver cancer: hepatoblastoma | Leidy Estefanía Zapata-Pavas | Received |
|
|||
| 14-PO7 | A multi-center comparison of Atezolizumab plus Bevacizumab and Lenvatinib as primary systemic therapy for unresectable hepatocellar carcinoma: focus on thrombotic and hemorragic adverse events | Marco Tizzani | Received |
|
|||
| 15-PO2 | The impact of transjugular intrahepatic portosystemic shunt on hepatocellular carcinoma : An analysis of a prospective cohort of liver transplant candidates | Sofia El Hajji | Received |
|
|||
| 15-PO6 | Impact of hepatitis C virus on reovirus immunotherapy for hepatocellular carcinoma | Adel Samson | Received |
|
|||
| 15-PO3 | Time-trends in cholangiocarcinoma mortality - a Danish nationwide cohort study | Morten Daniel Jensen | Received |
|
|||
| 15-PO1 | N-acetylcysteine prevents experimental hepatocellular carcinoma through modulation of the Nrf2 signaling pathway and promotion of antifibrogenic and antiproliferative effects | Fernando Caloca Camarena | Received |
|
|||
| 15-PO5 | Impact of ISO score on oncological outcomes and survival in liver transplant candidates with hepatocellular carcinoma | Elisa Pinto | Received |
|
|||
| 15-PO4 | Evaluation of Overall Survival using Restricted Mean Survival Time in Advanced Biliary Tract Cancer treated with Immunotherapy: Systematic Review and Meta-analysis. | Ezequiel Mauro | Received |
|
|||
| 15-PO7 | Did we apply the BCLC classification correctly? Results from the III hepatocellular carcinoma Registry of the Spanish Association for the Study of the Liver (AEEH) | MARIA VARELA | Received |
|
|||
| 16-PO5 | Immunotherapy-tyrosine kinase inhibitor sequences for patients with advanced hepatocellular carcinoma: a single center, retrospective, comparative study | Angelo Pirozzi | Received |
|
|||
| 16-PO3 | Therapeutic potential of HuR inhibition in chronic liver disease and hepatocellular carcinoma | Mickaël Jouve | Received |
|
|||
| 16-PO7 | Exploring self-reported occupational exposures in patients with MASLD-related hepatocellular carcinoma and/or cirrhosis: a prospective pilot study | Francesco Tovoli | Received |
|
|||
| 16-PO4 | Improved multiphase liver CT scan quality with implementation of a new contrast protocol | Anmol Gangi-Burton | Received |
|
|||
| 16-PO6 | Safety profile of the Add-on combination of Regorafenib with Nivolumab after treatment with atezolizumab-bevacizumab in treated patients with hepatocellular carcinoma. | Marco Sanduzzi Zamparelli | Received |
|
|||
| 16-PO2 | Profile of Immune-Related Adverse Events and Treatment Outcomes in First-Line Immunotherapy for Hepatocellular Carcinoma | Marta Fortuny | Received |
|
|||
| 16-PO1 | Safety and efficacy of Lenvatinib in very elderly patients with unresectable hepatocellular carcinoma | Silvia Camera | Received |
|
|||
| 17-PO1 | ASAP score may predict HCC recurrence after complete radiological response to locoregional treatments | Lorenzo Canova | Received |
|
|||
| 17-PO7 | Diagnostic performance of CT/MRI LI-RADS v2018 in non-cirrhotic steatotic liver disease | Justin Tse | Received |
|
|||
| 17-PO6 | Testicular receptor 4 and its role in metabolic liver disease | Marion Schweiger | Received |
|
|||
| 17-PO2 | Knowledge of ultrasound LI-RADS for hepatocellular carcinoma surveillance: a comparison between two centres | Anmol Gangi | Received |
|
|||
| 17-PO3 | Targeting sirtuins with novel indole derivatives: implications for anticancer activity in hepatocellular carcinoma | Deniz Kahraman | Received |
|
|||
| 17-PO5 | Tumor-derived extracellular vesicles: ultrasensitive detection using mid-infrared resonant nanostructures | Fabrizio Pizzolante | Received |
|
|||
| 17-PO4 | The role of adenosine monophosphate-activated protein kinase pathway in sinusoidal endothelial dysfunction during the pathogenesis of metabolic dysfunction-associated steatohepatitis-driven hepatocellular carcinoma | Mohammadjavad Sotoudeheian | Received |
|
|||
| 18-PO5 | Decoding human Intrahepatic Cholangiocarcinoma metabolism: unveiling the impact of SLC2A3 on aggressiveness and prognosis | Michela Anna Polidoro | Received |
|
|||
| 18-PO2 | The Potential Modulatory role of Aurora Kinase A on Yes-associated protein and Glycogen synthase kinase-3 beta in Advanced Chronic Liver Disease | Clarissa Joy Garcia | Received |
|
|||
| 18-PO1 | Rare but not forgotten - comprehensive molecular and histological analysis of liver yolk sac tumor and corresponding patient-derived cell line | Darko Castven | Received |
|
|||
| 18-PO6 | High prevalence of HCC among a diverse cohort of recently deceased persons with HCV | Mai Sedki | Received |
|
|||
| 18-PO7 | Population pharmacokinetic modeling of orally administered fostroxacitabine bralpamide (fostrox, MIV-818) and its metabolite troxacitabine in a phase I/IIa liver cancer study | Karin Ulrika Tunblad | Received |
|
|||
| 18-PO3 | Brg1 suppresses DEN-induced hepatocellular carcinogenesis in mice | Benedikt Kaufmann | Received |
|
|||
| 18-PO4 | A preliminary collection of tumoral and non-tumoral patient-derived organoids for the screening of personalized therapies in hepatocellular carcinoma | Elisa Monti | Received |
|
|||
Liver Cancer Summit 2024
22-24 February, Rotterdam
Search and consult posters online
in an exclusive section
for each poster
in an exclusive section
for each poster
ACTIVE FROM 22/02/2024 TO 24/02/2024
Poster
Gallery
Gallery
Upload
Poster
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
Forum
|
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.
|
|
||
|
||||
|
|
